
Speak with an onboarding specialist

Wegovy® is the only FDA-approved semaglutide in a pill for weight loss.
(Auto-renews monthly)
If prescribed $198 first month, then auto-renews at $248/mo.
If you don't see progress with full adherence, we'll refund your membership fees.

Wegovy® mimics a natural hormone in your body (GLP-1) that targets the areas of your brain that regulate appetite and food intake. By mirroring these natural signals, it helps you feel less hungry and more in control of your portions, leading to effective, clinical-grade weight loss.
The most common side effects of Wegovy® may include nausea, diarrhea, vomiting, constipation, stomach (abdomen) pain, headache, tiredness (fatigue), upset stomach, dizziness, feeling bloated, belching, low blood sugar in people with type 2 diabetes, gas, stomach flu, heartburn, and runny nose or sore throat. Tell your healthcare professional if you have any side effects that bother you or do not go away.
For full prescribing information and safety details, view the Wegovy® Medication Guide.
FuturHealth combines clinician-prescribed GLP-1 medications with personalized nutrition and Apple Fitness+ for a holistic approach to sustainable weight loss. This system is highly effective, with 28% of adults on the Wegovy® Pill losing up to 20% or more of their body weight.*
*28% of adults taking Wegovy® Pill lost 20% or more weight compared with 3% of adults taking placebo, based on 235 lb starting weight for Wegovy® Pill and 231 lb for placebo.
If prescribed $198 first month, then auto-renews at $248/mo.
*$198 first month, then auto-renews at $248/mo. Includes program membership and medication cost (any dose).
**If you don't see change by the end of your program with full adherence, we will give you your membership fees (excluding medical related costs tied to clinicians and pharmacy fees) back. It’s that simple. To qualify you must complete your in-app check-ins each week of the program.
Side effects of Wegovy® may include possible thyroid tumors. See here for details.
In a multi-national, double-blind clinical trial of over 17,000 patients with BMI of 27 or greater, weekly injections of semaglutide for a mean duration of 33 months reduced the risk of a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke by 20%. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232. doi:10.1056/NEJMoa2307563.